Globin Expression Cassettes With Insulators for Safer Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current globin vectors for treating β-thalassemia and sickle cell anemia face limitations such as non-erythroid activity leading to insertional oncogenesis and detrimental effects on vector production and transduction efficiency, making them unsafe and inefficient for patient treatment.
Innovation Solution
Development of expression cassettes with enhancer blocking insulators and specific globin locus control regions, including modified Dnase I hypersensitive sites, to achieve erythroid-specific and high-level globin gene expression with reduced risk of insertional oncogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional globin vectors are used for gene therapy, then globin gene expression is achieved, but insertional oncogenesis and non-erythroid activity occur
Solution Approach 1:
The patent extracts and removes the problematic enhancer elements from the vector construct, retaining only the minimal necessary components for globin gene expression. This eliminates the source of insertional oncogenesis while preserving therapeutic efficacy through the globin gene and its basic regulatory elements.
Solution Approach 2:
The patent introduces insulator elements as intermediary components between the globin gene and potential enhancers. These insulators act as protective barriers that prevent harmful enhancer activity while allowing necessary gene expression, thereby mediating between therapeutic need and safety requirements.
2Productivity
If enhancer elements are included in the vector, then globin gene expression is enhanced, but vector production is detrimentally affected
Solution Approach 1:
The patent removes problematic enhancer elements that interfere with vector production, thereby improving vector titers and production efficiency while maintaining adequate globin gene expression through alternative regulatory mechanisms.
Solution Approach 2:
The patent modifies the regulatory parameters of the globin gene expression system, using alternative promoters and minimal enhancer configurations that are compatible with high-level vector production while still achieving therapeutic gene expression levels.
3Reliability
If allogeneic bone marrow transplantation is used, then curative treatment is achieved, but graft rejection and graft-versus-host disease occur
Solution Approach 1:
The patent employs self-service by using the patient's own autologous hematopoietic stem cells that are genetically corrected in vitro, eliminating the need for allogeneic transplantation and its associated risks of graft rejection and graft-versus-host disease while maintaining curative potential.
Solution Approach 2:
The patent uses insulator elements as intermediaries to protect the integrated globin gene from positional effects and genomic instability, thereby ensuring long-term expression without requiring allogeneic transplantation.
4Ease of operation
If transfusion therapy is used, then anemia is corrected, but iron overload accumulates
Solution Approach 1:
The patent enables self-service by providing the patient's own corrected stem cells that can generate hemoglobin-producing red blood cells autonomously, replacing the need for lifelong external transfusions and thereby eliminating progressive iron overload from repeated transfusions.
Data Source
AI summary
The presently disclosed subject matter provides for expression cassettes that allow for expression of a globin gene or a functional portion thereof, vectors comprising thereof, and cells transduced with such expression cassettes and vectors. The presently disclosed subject matter further provides methods for treating a hemoglobinopathy in a subject comprising administering an effective amount of such transduced cells to the subject.